<DOC>
	<DOC>NCT00105521</DOC>
	<brief_summary>The purpose of this study is to determine if Sarizotan HC1 1 mg b.i.d. (taken twice a day) is effective in the treatment of dyskinesia associated with dopaminergic treatment of Parkinson's disease (PD).</brief_summary>
	<brief_title>Sarizotan HCl in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<criteria>The subject is an outpatient. The subject presents with a diagnosis of idiopathic Parkinson's disease. Prior therapy with all registered Parkinsonian medication is allowed. (For female subjects) The subject is pregnant or lactating. The subject is participating in another clinical study or has done so within the past 30 days. The subject has received neurosurgical intervention related to PD. The subject has relevant renal impairment. The subject has relevant hepatic impairment. The subject is suffering from any dementia or psychiatric illness. The subject has a history of allergic asthma.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Parkinson's Disease</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>Dyskinesia associated with dopaminergic treatment</keyword>
</DOC>